股本结构
单位：万股
| 公告日期 | 2025-11-10 | 2025-08-12 | 2025-03-26 | 2024-11-12 | 2024-11-12 | 2024-08-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 15913.17 | 15909.69 | 15900.03 | 15514.56 | 15473.45 | 15385.25 |
| 普通股本 | 79565.85 | 79548.44 | 79500.14 | 77572.80 | 77367.23 | 76926.26 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-10 | 2025-08-11 | 2025-03-25 | 2024-11-11 | 2024-09-30 | 2024-08-12 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：5
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-10 | 79565.85 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-08-12 | 79548.44 | 未披露 | 定期报告 | 2025-08-11 |
| 2025-03-26 | 79500.14 | 未披露 | 定期报告 | 2025-03-25 |
| 2024-11-12 | 77572.80 | 未披露 | 定期报告 | 2024-11-11 |
| 2024-11-12 | 77367.23 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of share options
Delivery of shares on vesting of performance based restricted stock units
Delivery of shares on vesting of restricted stock units
|
2024-09-30 |
| 2024-08-13 | 76926.26 | 未披露 | 定期报告 | 2024-08-12 |
| 2024-08-13 | 76882.13 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of share options
Delivery of shares on vesting of performance based restricted stock units
Issuance of shares, net of discount
|
2024-06-30 |
| 2024-06-14 | 76402.00 | 未披露 |
更多>>
ADSs offered 12,531,300 ADSs by the company
|
2024-06-17 |
| 2024-05-15 | 70136.35 | 未披露 | 定期报告 | 2024-05-15 |
| 2024-04-24 | 70135.78 | 未披露 | 定期报告 | 2024-04-18 |
| 2024-05-15 | 70134.94 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise of share options
Delivery of shares on vesting of restricted stock units
|
2024-03-31 |
| 2024-03-27 | 70128.70 | 未披露 | 定期报告 | 2024-02-29 |
| 2023-09-07 | 70121.71 | 未披露 | 定期报告 | 2023-08-31 |
| 2023-03-28 | 62492.85 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Financing cash flows
Changes in foreign exchange
Interest expense
|
2022-12-31 |
| 2022-03-31 | 58490.82 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of share capital, net
Conversion of loan notes and warrants
Exercise of share options
|
2021-12-31 |
| 2021-08-05 | 54451.03 | 未披露 | 定期报告 | 2021-06-30 |
| 2021-03-31 | 54122.63 | 未披露 | 定期报告 | 2021-02-28 |
| 2021-02-12 | 51535.13 | 未披露 |
更多>>
1.ADSs offered by the company 34,500,000 ADSs.
|
2021-02-12 |
| 2021-03-31 | 33895.31 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of share capital, net
Issuance of share capital on conversion of loan notes
Conversion of warrants
|
2020-12-31 |
| 2020-09-29 | 33871.40 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-06-15 | 21365.25 | 未披露 | 定期报告 | 2020-06-08 |
| 2020-03-06 | 12450.79 | 未披露 | 定期报告 | 2020-03-01 |
| 2020-02-18 | 11225.51 | 未披露 | 定期报告 | 2020-02-11 |
| 2019-09-17 | 9795.96 | 未披露 |
更多>>
from January 1, 2019 to June 30, 2019
Issued on April 23, 2019 for OncoMed acquisition
Issued on June 21, 2019 for conversion of loan note
|
2019-06-30 |
| 2019-04-24 | 9602.54 | 未披露 | 定期报告 | 2019-04-24 |
| 2019-04-29 | 7124.03 | 未披露 | 定期报告 | 2018-12-31 |
| 2018-03-23 | 7109.50 | 未披露 | 定期报告 | 2018-03-01 |
From June 30, 2024 to September 30, 2024
Exercise of share options
Delivery of shares on vesting of performance based restricted stock units
Delivery of shares on vesting of restricted stock units
From March 31, 2024 to June 30, 2024
Exercise of share options
Delivery of shares on vesting of performance based restricted stock units
Issuance of shares, net of discount
ADSs offered 12,531,300 ADSs by the company
From December 31, 2023 to March 31, 2024
Exercise of share options
Delivery of shares on vesting of restricted stock units
From December 31, 2021 to December 31, 2022
Financing cash flows
Changes in foreign exchange
Interest expense
From December 31, 2020 to December 31, 2021
Issuance of share capital, net
Conversion of loan notes and warrants
Exercise of share options
1.ADSs offered by the company 34,500,000 ADSs.
from December 31, 2019 to December 31, 2020
Issuance of share capital, net
Issuance of share capital on conversion of loan notes
Conversion of warrants
from January 1, 2019 to June 30, 2019
Issued on April 23, 2019 for OncoMed acquisition
Issued on June 21, 2019 for conversion of loan note